



Asian Journal of Chemistry; Vol. 26, No. 16 (2014), 4940-4948

ASIAN JOURNAL OF CHEMISTRY

<http://dx.doi.org/10.14233/ajchem.2014.16825>



REVIEW

Terpenoids and Its Commercial Utility from Neem: The Nature's Own Pharmacy

A.S. SATHISH KUMAR^{1,*}, KOTTE SUBHASH CHANDRA BOSE², K.V.T.S. PAVAN KUMAR¹, SHRIRAM RAGHAVAN¹ and P.M. MURALI^{1,2}

¹Dalmia Centre for Research & Development, 10/8, Bharathi Park Main Road, S.A.H.S.C Post, Saibaba Colony, Coimbatore-641 043, India

²Evolva Biotech Private Limited, TICEL Bio Park Limited, Taramani, Chennai-600 113, India

*Corresponding author: E-mail: satkut@yahoo.com

Received: 6 December 2013;

Accepted: 4 February 2014;

Published online: 28 July 2014;

AJC-15606

Plant derived bio products have become integral part of world health care system which not only include botanical drugs but also agro chemicals, cosmetics, nutraceuticals, flavors and fragrances and so on. The World Bank estimates that global trade in plant derived products will grow at average 10-12 % per year and will reach whopping USD 123 billion by 2020. Inevitably this brought attention to our sthala vriksha or sacred tree neem (*Azadirachta indica*) considered as store house of high value products with vast array of biological activities like insecticidal, spermicidal, anticancer, hypoglycemic, antiulcer, antiinflammatory, and many more. However due to inherent complexities in scalability which includes consistent supply chain and difficulty in synthesizing bioactive metabolites using established chemical routes and seasonal variation in bio-efficacy with change in plant chemistry, place, age *etc.* makes large scale production of most of them is impossible. Hence there is need for a paradigm shift in combining traditional approaches with more sophisticated biotechnological methods to produce these products in heterologous system, thereby enabling a consistent scale-up at a commercial level. This article reviews the terpenoids reported in neem so far, their proposed biosynthetic pathways and potential avenues for expressing them in microbial cell factories.

Keywords: *Azadirachta indica*, Isoprenoids, Medicinal plants, Plant secondary metabolites.

INTRODUCTION

Azadirachta indica (neem), a versatile tree of immense value, is native to the Indian sub-continent belongs to the Meliaceae family has attained a pride of place in international scientific research and literature because of its diverse utility in pharmaceuticals, cosmetics, agriculture, veterinary, toiletries and as potential biomass¹ Therapeutic frequency index (TI) attributed to Neem is high and hence categorized under "elite species" due to its curative abilities in treating more than 25 critical human ailments and still currently being explored and widen the horizon to include FMCG, Agro and OTC products². Neem tree, owing to its well-known therapeutic, pharmaceutical, agro, medicinal properties, is variously known as "Divine tree," "Heal all," "the wonder tree", "Nature's drug store," and "Village pharmacy"³. Diverse application of neem tree for mankind has been known since ages, as evident from its mention in various ancient Indian documents (Vedas, 2000 - 4000 BC) like '*Charak-Samhita*' and '*Susruta-Samhita*'. Indian system of natural treatment, Siddha and Ayurveda refers to neem tree as "*Kaya Kalpam*" (The name is from the Sanskrit language - kaya: body and kalpa: rejuvenation and "*Sarva Roga*

Nivarini" (in Sanskrit, meaning "The curer of all ailments"), respectively⁴.

Due to its plethora of biological activities it is the most researched tree in the world and is considered to be the most promising tree of 21st century⁵. In fact, scientific community believe that even half the qualities of this wonder tree hasn't discovered and every year there are additional reports for neem's new properties or chemistry. Almost every part of the tree such as fruits, seeds, leaves, bark and roots has long been used in traditional systems of medicines for the treatment of a variety of human diseases. *A. indica* is one of the most extensively studied plants globally and over 300 constituents have been isolated from its different parts and their structures were elucidated. Neem's extensive biological activities and FMCG applications (for example: cosmetics, toiletries *etc.*) are mainly due to its richness in secondary metabolites in which majority of them belongs to the class of isoprenoids⁶.

Neem terpenoids current status: Since times immemorial, neem derived products have been used for food, medicine and agriculture leading to the common phrase "Nature's Pharmacy" for human welfare. Terpenoids are the majority among the secondary metabolites present in the neem (Fig. 1)




Fig. 1. Pie chart representing the major groups of neem secondary metabolites. Based on their numbers and diversity, terpenoids appeared to be capturing major portion and much potential in having assortment of industrial and medicinal applications




Fig. 2. Classification of Neem Terpenoids


and they are categorized into various classes (Fig. 2) which are detailed in the following sections.

Elucidation of terpenoids from neem was dates back to 1942; Siddiqui was the first to report the isolation of nimbin, nimbidin and nimbinin. Since then more than 200 terpenoids have been characterized from different parts of neem and well-studied by various scientists in classifying these compounds.⁷⁻⁸

Monoterpenoids: Monoterpenoid, dihydromyrcenol is the first to be reported from the extract of neem fruit coats⁹. Other monoterpenes like α and β -Pinene, limonene, Myrcene, Camphene are also reported to be present in neem¹⁰.

Diterpenoids: Podocarpanoids and abeitanooids are the two major groups of neem are reported so far. Twenty four compounds belonging to these groups (for example: sugiol, nimbiol, nimbosone, nimbilicin) are extracted from neem bark or root¹¹. (Fig. 3).

Triterpenoids: Apart from β -amyrin which is a common triterpenoid present in all plants, many of neem plant specific triterpenoids are discovered and constitute the major group of isoprenoids. Based on current discovery status neem triterpenoids can be classified into nine groups¹². *i.e.* Protomeliacians or Protolimonoids, Mononortriterpenoids, Dinortriterpenoids, Trinortriterpenoids, Tetranortriterpenoids, Pentanortriterpenoids, Hexanortriterpenoids, Octanortriterpenoids, Nonanortriterpenoids



Name	R	R ₁	R ₂
Azadirin A	H	Me	(CH ₂) ₂ OH
Azadirin B	H	(CH ₂) ₂ OH	Me
Margocilin	β -OH,H	OH	i-Pr
Margocin	O	H	i-Pr
Margocinin	O	OH	MeCHCH ₂ OH
Nimbiol	H ₂	OH	OH
Nimolinin	H ₂	OH	Ac
Nimbisonol	β -OH,H	OH	Me
Demethylnimbionol	β -OH,H	OH	OH
Isomargolonone	O	COOH	Me
Margolone	H ₂	Me	COOH
Margolonone	O	Me	COOH
Methylnimbiol	H ₂	OMe	i-Pr
Nimosone	O	OH	i-Pr
Methylnimbionone	O	OMe	OMe
Nimbione	O	Me	OH
Nimbinone	O	OH	Me
Nimbionol	β -OH,H	OH	OMe
Nimbionone	O	OH	OMe
Nimbonone	H ₂	Et	OMe
Nimbiol	H ₂	OH	i-Pr
Sugiol	H ₂	OH	Me

Fig. 3. Diterpenoids of neem (belong to two groups, podocarpanoids and abeitanooids)

Protomeliacians or protolimonoids: Protolimonoids (Euphol or Tirucallol derivatives) are thought to be biosynthetic precursor for meliacins or limonoids and so called protomeliacians¹³.

Presence of twelve types of protolimonoids has so far demonstrated in neem plant (Fig. 4) in which meliantriol is one of the potent antifeedant molecule and is considered to be the first tetracyclic triterpenyl alcohol biogenetically related to tirucallol¹⁴.

Mononortriterpenoids: Melianol (Fig. 5) is a ring C *sec*-mononortriterpenoid was isolated from neem leaves¹⁵ and is the only one belong to this class was identified so far in neem plant.

Dinortriterpenoids: Three compounds azadirolic acid, azadiradionol and meliacinin (Fig. 5) belong to this class which is reported to be isolated from fruit coats¹⁶.

Trinortriterpenoids: Limbonin, meliacinolactol and Zeeshanol are the ones considered to be part of trinortriterpenoids¹⁷ (Fig. 5).

Tetranortriterpenoids: Tetranortriterpenoids are the major isoprenoids constitutes in large numbers with varied modified carbon chains in neem.

Azadirones: The unique feature of azadirone groups is the presence of oxygen function at C-3 and C-7 with no change in all the four rings of the basic skeleton. Meliacins of this family are further sub grouped into azadirone, azadiradione and epoxy-azadiradione in which oxidation reactions makes them related to each other¹⁸ (Fig. 6).




Fig. 4. Examples for protolimonoids or protomeliacins

Two compounds 17-hydroxy azadiradione and 17-hydroxyl nimbocinol which are related to azadirones are reported to have toxicity to termites. Bactericidal activity was reported for epoxy azadiradiones like nimbin and epoxy nimbin¹⁹.

Gedunins: Gedunin is one of the potent bioactive tetranortriterpenoids of neem reported to have anticancer, antifilarial, antifungal and antimalarial properties. The D-ring in parent structure of nimbinin, nimbocinol and 17 β and 17 α hydroxyl azadiradione are considered to be oxidized probably by Baeyer Villiger type of reaction to give rise to gedunins²⁰ (Fig. 7).

Amoorstatin and vepinins: The biogenic precursor for these compounds could be nimocinol or other azadirones formed through addition of 17-OH to the C-14/15 double bond and formation of 7 α and 17 α -oxygen bridge. Amoorstatins possess a C-19/29 oxygen bridge and reported for its hypoglycemic activity²¹ (Fig. 7).

Vilasinin: Vilasinin is considered to be a key intermediate in the biosynthesis of C-seco meliacins namely nimbin, salanin and azadirachtins. It is reported that vilasinins with C-12 substituent did not show considerable antifeedant activity as compared with vilasinin compounds with without C-12 substituent²² (Fig. 7).

C-seco meliacins: Cleavage of carbon ring C of parent compound gives the name C-seco for these meliacin compounds.

C-seco meliacins are the most important group of tetranortriterpenoids in neem having with structural complexity and numerous biological activities. One of the sub groups of C-seco meliacin family is potent insecticidal compound called azadirachtin which gives the uniqueness to entire neem chemical constituents^{23,24}. Several analogs/derivatives of azadirachtin have been reported (Fig. 8) which includes isolation from neem and chemical modifications.

Pentanortriterpenoid: Nimbinene, 6-deacetylnimbinene, nimbandirol, 6-O-acetylnimbandirol and 4 α -benzoylnimbandirol are the five compounds belong to this class were reported so far²⁵.

Hexanortriterpenoids: Nimolicinolic acid and nimboicin were isolated from fruits and root bark, respectively (Fig. 9). Nimolicinolic acid is considered to be the unique compound isolated from neem has apo-euphane or apo-tirucallane skeleton while other plants possess cucurbitacin, dammarane and lanostane skeletons²⁶.

Octanortriterpenoids: Four compounds desfuranoazadiradione, azadiranol, desfurano-6 α -hydroxyazadiradione and desfurano-desacetylnimbin were reported to belong to this class²⁷ (Fig. 9).

Nonanortriterpenoids: β -Nimalactone and α -nimalactone are the only two compounds reported to belong to this class²⁸ (Fig. 9).




Fig. 5. Structures of mononortriterpenoids, dinortriterpenoids, trinortriterpenoids and pentanortriterpenoids




Fig. 6. Structures of azadirone family

Sesquiterpenoids: First sesquiterpenoid identified in neem was the methyl (2E, 6E)-farnesoate isolated from fruit coats. Various sesquiterpenoids identified from neem include β-farnesene, Caryophyllene, Germacrene B, Valencene and α-Himachalene²⁹.

Full potential still largely untapped: Plant steroids and terpenoids based bio products account for USD 12.4 billion global market per annum³⁰. According to leading market survey company BCC research, the global market for botanical and plant-derived drugs is expected to reach USD 26.6 billion in 2017 with a compound annual growth rate (CAGR) of 3.7 %.

All the parts of the neem tree find extensive application and usage in natural system of Indian medicines like Ayurvedha and Siddha. Modern day medicine has identified a wide range of activities from various parts of the neem tree. These actions include azadirachtolide: anti-hyperglycemic and anti-lipidemic, Nimbin and Nimbidin: anti-inflammatory, anti-pyretic, antihistamine, anti-arrhythmic, anti-fungal, anti-ulcer, Nimbidol: anti-tubercular, anti-malaria, Gedunin-vasodilator, sodium nimbinate: spermicidal, salanin: repellent *etc*³¹.

Though neem has proved a promising tree, yet lot of research is required to prove its multiple uses to mankind. However the success rate for neem derived products into commercialization is low and promising products often languish through lack of volume generation because of numerous reasons. Large scale extraction of important secondary metabolites from neem suffers with lack in high purity coupled by lower yields and high cost, which in turn, leads to compromise in quality and bio efficacy.

Another challenging arena is the huge batch to batch variability which in turn leads to lack of reproducible bio-activity. In addition, a scale up to address huge market demand requires a lot of biomass (plants) which in turn has a negative carbon footprint. Moreover, chemical synthesis of such molecules is often impeded by its long and protracted synthetic routes and also difficulty in separation due to several chiral centres. It took 22 years of hard work to synthesize azadirachtin³². Total number of steps to synthesize it chemically is 71 and the final yield is a meager 0.00015 %. This also has an impact on the affordability of such molecules for widespread




Fig. 7. Structures of some of tetranortriterpenoids class of compounds




Fig. 8. Salannin family is featured with two oxygen bridges, C-6/28 and C-7/14. Azadirachtin is the complex molecule with numerous oxygen atoms and it's a most potent insect anti-feedant




Fig. 9. Structures of hexanortriterpenoids, octanortriterpenoids and nonanortriterpenoids

therapeutic application. Formulation based large scale commercialization also not able to deliver at affordable prices because of fragile natural source of supplying seeds with reliable terpenoid content and extraction³³.

In order to effectively address these challenges, production of neem terpenoids in heterologous systems will ensure a stable supply chain at affordable prices. Despite decades of research, genes involved in neem secondary metabolism remains poorly characterized. Development of neem plant genome and transcriptomics is still in budding stage. Recently genome and transcriptome sequencing of neem have been reported indicating the discovery of potential genes involved in terpenoid biosynthesis³⁴. However genetic maps of biosynthetic pathways are still far from complete, whereas knowledge on the regulation of these pathways is practically nonexistent. As a result, the diversity of genes encoding enzymes involved in neem's secondary metabolism is not well represented, or at least not well annotated in public DNA sequence databases.

Neem is known to produce a bewildering array of specialized terpenoid metabolites based on a myriad of skeletal isoprenoid structures and functional group combinations. Given their enormous structural diversity and the equally staggering numbers of terpenoid molecules produced, the impressive biosynthetic pathways for these molecules are yet to be tapped. Functional genomics based deciphering of the biosynthetic pathways/genes for neem terpenoids could be the key issue for its industrial production.

Harnessing enzymes from neem to engineer terpenoids with commercial potential: Elucidation of entire pathway for neem terpenoid pathway genes can be used for metabolic engineering. Also the entire biosynthetic pathways could be transferred to other hosts such as *E. coli* or yeast to produce desired molecule in industrial scale. Gene or pathway information for neem terpenoid biosynthesis is sparse however based on radiolabel based studies, it was postulated that azadirachtin biosynthesis precursors are derived from mevalonate pathway in which cyclization of squalene results into

tetracyclic ions euphane/euphol and tirucallane/tirucallol two chemically similar compounds³⁵.

Euphane/tirucallane is the first biogenic precursor formed from cyclization of squalene which is then further cyclized and addition of furan ring is catalyzed by the unknown enzymes to give rise to limonoids such as azadirone and azadiradione. Allylic isomerization of euphane/tirucallane give rise to butyrospermol, which is then oxidized and rearranges through a Wagner-Meerwein (W-M) reaction by 1,2 methyl shift to form apo euphane/tirucallane. Cleavage reactions of four terminal carbons on the side chain leads to formation of a tetranortriterpenoid intermediate (Fig. 10) and upon cyclization of remaining carbons on the side chain give rise to furan ring which is finally oxidized to form azadirone and azadiradione. *Ciseco*-limonoids such as nimbin, nimbidinin and salannin are formed from either of azadirone or azadiradione molecules

through oxidation and esterification with a molecule of tiglic acid, a derivative of L-isoleucine. It is postulated that azadirachtin and related analogues are biosynthesized upon further oxidation and cyclization of azadirone and salannin³⁶.

Terpenoid cyclases or synthases catalyzes the formation of parent scaffolds of the various monoterpene, sesquiterpene and diterpene types from these key precursors. Terpenoid synthases catalyzes the intermolecular electrophilic coupling reaction with various cyclizations and rearrangements, including hydride shifts, methyl migrations and Wagner-Meerwein rearrangements, which largely contributes to the great structural diversity and vast array of terpenoids. Subsequent biosynthetic steps involving terpenoid skeleton modifications like oxygenation or hydroxylation are often catalyzed by cytochrome P450s (CYPs)³⁷. Thus the biosynthesis of neem terpenoids involves very complex oxidation and cyclization reactions




Fig. 10. Proposed biosynthesis pathway of azadirachtin and other related limonoids

presumed to be catalyzed by series of enzymes namely terpenoid synthases or cyclases and CYPs. In neem, biosynthesis of euphane/ tirucallane which is the primary precursor for limonoids could be possibly catalyzed by terpene synthases. Multifunctional CYPs then modifies euphane/ tirucallane to form several terpenoids.

Terpenoid biosynthesis has been well established in various host systems like *Escherichia coli*, or *Saccharomyces cerevisiae* or insect cells. For example, successful demonstration of terpenoid pathways like taxol and artemisinin in hosts other than plants has led to large-scale microbial production³⁸. Production of amorphadiene up to 24 mg/L was achieved in *E. coli*³⁹. Taxadiene was successfully biosynthesized in *Saccharomyces cerevisiae* by combining eight genes out of ten of the taxol biosynthetic pathway⁴⁰.

With advent of bioinformatics tools combines with enzymology and protein chemistry, production of potential neem metabolites in heterologous system is now feasible.

Conclusion

Considering the rapid advances in neem terpenoid knowledge and potential commercial uses, it is conceivable that genes involved in secondary metabolite biosynthesis of this plant to be explored. With advent of next generation sequencing facilities in its fold, it is now possible to integrate modern genomic tools with existing data to dissect the metabolic pathways and the role of key genes associated with their regulation. Neem pathways/genes can then be subject to new metabolic engineering efforts and applications.

High value neem compounds produced in heterologous hosts like *E. coli* or *Saccharomyces cerevisiae* which is considered as generally recognized as safe (GRAS) offers the potential for increased functionality and quality at lower production costs, including metabolites of great significance to human welfare [as drugs, fast-moving consumer goods (FMCG), nutraceuticals, cosmetics, over-the-counter (OTC)] such as anti-spermidicidal, antiviral, anticancer, antibacterial, anti-inflammatory, anti-ulcer antimalarial, bio pesticides *etc.* which are of utmost relevance to Indian sub-continent. Also the production of high value neem products in a non-plant host has huge impacts on sustainability and the protection of the environment, human health, industrial competitiveness and capable of generating growth.

ACKNOWLEDGEMENTS

The authors thank the Management of Dalmia Centre for Research & Development Coimbatore and Evolva Biotech Pvt. Ltd, India for providing necessary research facilities.

REFERENCES

- P.M. Murali, K. Nalini and S. Lakshmisubramaniam, Tree Science Conference, New Delhi, pp. 46 (1998).
- T.R. Govindachari, *Curr. Sci.*, **63**, 117 (1992).
- P. Sharma, L. Tomar and M.B.V. Bachwani, *Int. Res. J. Pharmacy*, **2**, 97 (2011).
- H.S. Puri, *Neem, The Divine Tree, Azadirachta indica*, Harwood Academic Publications, Amsterdam, The Netherlands, pp. 90 (1999).
- A. Tomar, *Neem: An Introduction*; In: *Neem: A Treatise*, I.K. International Publishing House Pvt Ltd., New Delhi, Ch. 1, pp. 3-19 (2009).
- A. Tomar, *Neem in Health and Cosmetics*; In: *Neem: A Treatise*, I.K. International Publishing House Pvt Ltd., New Delhi, Ch. 31, pp. 461-485. (2009).
- B.S. Siddiqui, S.T. Ali and S.K. Ali, *Chemical Wealth of Azadirachta indica (Neem)*; In: *Neem: A Treatise*, I.K. International Publishing House Pvt Ltd., New Delhi, Ch 13, pp. 171 (2009).
- N. Saxena and Y. Kumar, *Chemistry of Azadirachtin and other Bioactive Isoprenoids from Neem (Azadirachta indica A. Juss)*; In: *Neem: A Treatise*, I.K. International Publishing House Pvt Ltd., New Delhi, Ch 14, pp. 208 (2009).
- B.S. Siddiqui, M. Rasheed, F. Ilyas, T. Gulzar, R.M. Tariq and S.N.H. Naqvi, *Z. Naturforsch.*, **59c**, 104 (2004).
- A.H. Wafaa, Hassan Amer, Nefisa, M.A., EL-Shayeb, *J. Appl. Sci. Res.*, **3**, 1050 (2007).
- I. Ara, B.S. Siddiqui, S. Faizi and S. Siddiqui, *Phytochemistry*, **28**, 1177 (1989).
- Rasheed, Ph.D. Dissertation, Studies on the Chemical Constituents of *Azadirachta indica* A. Juss (Neem), University of Karachi, Pakistan (2002).
- S. Siddiqui, B.S. Siddiqui and S. Faizi, *Planta Med.*, **51**, 478 (1985).
- S. Siddiqui, S. Faizi, B.S. Siddiqui and Ghiasuddin, *J. Nat. Prod.*, **55**, 303 (1992).
- B.S. Siddiqui, F. Afshan, T. Gulzar, R. Sultana, S.N.-H. Naqvi and R.M. Tariq, *Chem. Pharm. Bull. (Tokyo)*, **51**, 415 (2003).
- B.S. Siddiqui and M. Rasheed, *Helv. Chim. Acta*, **84**, 1962 (2001).
- S. Siddiqui, T. Mahmood, B.S. Siddiqui and S. Faizi, *Heterocycles*, **26**, 1827 (1987).
- T.R. Govindachari, B. Suresh, G. Gopalakrishnan, B. Banumathy and S. Masilamani, *Phytoparasitica*, **26**, 109 (1998).
- S.M. Lee, J.L. Olsen, M.P. Schweizer and J.A. Klocke, *Phytochemistry*, **27**, 2773 (1988).
- D. Lavie, M.K. Jain and S.R. Shpan-Gabrielith, *Chem. Commun.*, 910 (1967).
- C.R. Narayanan, R.V. Pachapurkar, B.M. Sawant and M.S. Wadia, *Indian J. Chem.*, **7**, 187 (1969).
- A. Akhila, G. Adam, K. Rani, J. Schmidt and B. Schneider, *Fortschr. Chem. Org. Naturst.*, **78**, 147 (1999).
- G.E. Veitch, A. Boyer and S.V. Ley, *Angew. Chem.*, **47**, 9402 (2008).
- C. Devakumar and R. Kumar, *Curr. Sci.*, **95**, 573 (2008).
- S.R. Rojatar, V.S. Bhat, M.M. Kulkarni, V.S. Joshi and B.A. Nagasampagi, *Phytochemistry*, **28**, 203 (1989).
- I. Ara, B.S. Siddiqui, S. Faizi and S. Siddiqui, *Phytochemistry*, **27**, 1801 (1988).
- B.S. Siddiqui, F. Afshan and S. Faizi, *Tetrahedron*, **57**, 10281 (2001).
- M. Bokel, R. Cramer, H. Gutzeit, S. Reeb and W. Kraus, *Tetrahedron*, **46**, 775 (1990).
- W.A. Helmy, H.I. Abd-Alla, H. Amer and M.M. El-Safty, *Australian J. Basic Appl. Sci.*, **1**, 801 (2007).
- K. Muffler, D. Leipold, M.-C. Scheller, C. Haas, J. Steingroewer, T. Bley, H.E. Neuhaus, M.A. Mirata, J. Schrader and R. Ulber, *Process Biochem.*, **46**, 1 (2011).
- K. Biswas, I. Chattopadhyay, R.K. Banerjee and U. Bandyopadhyay, *Curr. Sci.*, **82**, 1336 (2002).
- J. Jauch, *Angew. Chem.*, **47**, 34 (2008).
- M.B. Isman, *Phytoparasitica*, **25**, 339 (1997).
- N.M. Krishnan, S. Pattnaik, P. Jain, P. Gaur, R. Choudhary, S. Vaidyanathan, S. Deepak, A.K. Hariharan, P.G. Krishna, J. Nair, L. Varghese, N.K. Valivarthi, K. Dhas, K. Ramaswamy and B. Panda, *BMC Genomics*, **13**, 464 (2012).
- K. Rani and A. Akhila, *Nat. Prod. Lett.*, **4**, 179 (1994).
- P.M. Dewick, *Medicinal Natural Products: A Biosynthetic Approach*, John Wiley & Sons, New York, edn 2 (2002).
- E.M. Davis and R. Croteau, *Curr. Topics Chem.*, **209**, 53 (2000).
- P.K. Ajikumar, K. Tyo, S. Carlsen, O. Mucha, T.H. Phon and G. Stephanopoulos, *Mol. Pharm.*, **5**, 167 (2008).
- J.D. Newman and J. Chappell, *Crit. Rev. Biochem. Mol. Biol.*, **34**, 95 (1999).
- J. Kirby and J.D. Keasling, *Annu. Rev. Plant Biol.*, **60**, 335 (2009).